Technical
Channels

Drug Discovery

Drug Development

Drug Manufacturing

Drug Delivery

Clinical Trials

Regulatory and Legal

Alliances and Mergers

QA/QC and Compliance

Pharmaceutical Processing and Packaging

Change text size [+] [-]

IntegraGen: First Certified French Service Provider For Illumina Goldengate And Infinium Genotyping

Friday, June 22, 2007
 Email This |  Printer Friendly

Illumina, Inc. said IntegraGen SA has received Illumina Certified Service Provider (CSPro) certification for GoldenGate and Infinium genotyping technologies.

The GoldenGate assay is Illumina's first array-based platform that combines high-sample throughput, high multiplexing, and single-site CpG resolution for DNA methylation profiling.

The Infinium Whole-Genome Genotyping BeadArray solution offers single or multi-sample BeadChip formats and high-density architecture with the flexibility to add additional custom SNP Assays.

Illumina, a San Diego-based company, is a leading developer, manufacturer, and marketer of next-generation life science tools and integrated systems for the analysis of genetic variation and biological function.

As a customer of IntegraGen, Jessica Zucman-Rossi, M.D., Ph.D., has been using Illumina technology in a pilot study for loss of heterozygosity (LOH) analysis in liver tumors at the Human Polymorphism Study Center (CEPH) in Paris.

"We also chose Illumina technology to test for promoter methylation in liver tumors because there were a large number of genes available for testing with this system, and the ability to quantify methylation levels is a real advantage. My team was able to analyze a large number of samples in each experiment, and the time taken to generate results was short, generating a large amount of data," said Dr Zucman-Rossi.

"The results we attained were excellent, achieving methylation profiling of 96 tumor samples on more than 1,500 CpG. The data are robust, and we are currently preparing a second series of samples."

IntegraGen is a personalized healthcare company focused on the development and commercialization of molecular diagnostic tests for complex diseases and provider of genetic services.


Share this:   Del.icio.us | 
Digital Edition



Singapore's Preclinical R&D industry should differentiate itself in Asia by competing on quality rather than on price.
Yes
No
View results


ABOUT PHARMA ASIA | FREE SUBSCRIPTION | CONTACT US

© 2010 Ten Alps Communications Asia. All rights reserved.
Use of this Web site is subjected to its Terms and Conditions of Use. View our Privacy Policy